ArticleJournal of ovarian research2026
The Bushen Huatan formula inhibits TP53-Mediated ferroptosis and modulating lipid metabolism in polycystic ovary syndrome abnormalities rat model.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundBushen Huatan Formula (BSHT) shows promise in treating reproductive endocrine disorders, yet its mechanism in polycystic ovary syndrome (PCOS) remains unclear. This study aims to elucidate the specific mechanism of action of BSHT in treating PCOS.
methodsPCOS model in rats was established by using a high-fat diet combined with letrozole gavage, and an in vitro model was constructed by stimulating human ovarian granulosa cells with dehydroepiandrosterone. Oestrus cycle changes were monitored throughout the BSHT intervention period via daily vaginal smear. Following intervention, ovarian histopathology and serum sex hormones, lipid profiles, oxidative stress, and ferroptosis markers were assessed. Network pharmacology predicted BSHT targets and pathways, validated in vitro/in vivo via TP53 pathway expression and downstream factors, oxidative stress, and key ferroptosis protein levels.
resultsHigh-dose BSHT effectively improved estrous cycle irregularities, reduced ovarian and uterine indexes, and repaired ovarian pathology in PCOS rats. BSHT treatment significantly improved endocrine profiles by reducing testosterone and luteinizing hormone levels while increasing follicle-stimulating hormone (P < 0.001), and ameliorated dyslipidemia by lowering total cholesterol and low-density lipoprotein cholesterol while elevating high-density lipoprotein cholesterol (P < 0.001). Mechanistically, BSHT suppressed oxidative stress and ferroptosis, as evidenced by decreased malondialdehyde, reactive oxygen species, lipid peroxides, Fe2 + and ACSL4, along with increased GSH and GPX4 (P < 0.001). Both network pharmacology and experimental validation confirmed that these effects were mediated through inhibition of the TP53 signaling pathway and its downstream targets (P < 0.001). The critical role of TP53 was further verified through intervention studies using ferroptosis inhibitors and TP53 agonists (P < 0.001).
conclusionThis study demonstrates that BSHT alleviates PCOS pathology by inhibiting ferroptosis and regulating lipid metabolism via the TP53 signaling pathway, providing a theoretical basis for novel therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.